FDA-Approved Drug AMD3100 Overcomes Immunotherapy Resistance in Rare Liver Cancer
核心洞察
Cornell University researchers discovered that fibrolamellar carcinoma (搜索) tumors sequester immune T cells (搜索) away from cancer cells, explaining why immunotherapy fails in this rare liver cancer (搜索).
The FDA-approved drug AMD3100 successfully mobilized T cells (搜索) into tumor cores and enhanced immune checkpoint inhibitor effectiveness in patient tumor samples.
The combination treatment led to significant increases in tumor cell death, offering new hope for fibrolamellar carcinoma (搜索) patients who currently have no cure.
A breakthrough study from Cornell University has identified why immunotherapy fails against fibrolamellar carcinoma (搜索), a rare and fatal liver cancer (搜索), and demonstrated that an existing FDA-approved drug can restore the immune system's ability to fight the disease. The research, published February 17 in Gastroenterology, reveals a novel mechanism of immune evasion and offers a potential treatment pathway for patients who currently have no cure.
Rare Cancer with Limited Treatment Options
Fibrolamellar carcinoma (搜索) primarily affects children and young adults, accounting for up to 2% of all liver cancers. The disease currently has no cure and often metastasizes by the time of detection, leaving patients with short life expectancy. Unlike other liver cancers that respond well to immune checkpoint inhibitors (搜索), fibrolamellar carcinoma has remained resistant to immunotherapy approaches.
Uncovering the Mechanism of Immune Evasion
Using single-nucleus transcriptomics technology, researchers discovered that fibrolamellar tumors actively rewire their local microenvironments to sequester immune T cells (搜索) away from cancer cells—a process called T-cell exclusion. This mechanism prevents the body's immune system from accessing and attacking the tumor, explaining the poor response to immunotherapy.
"Our results provide among the first indications of why a type of immunotherapy called immune checkpoint inhibition hasn't worked well in these patients," said Praveen Sethupathy, professor of physiological genomics and co-senior author of the study. "Even if this particular drug isn't the end-all-be-all, it teaches us that this T-cell exclusion phenomenon is an important one to tackle in fibrolamellar carcinoma (搜索)."
The research team identified that stellate cells (搜索), normal liver cells modified by cancer, create the characteristic thick fibrous bands that give fibrolamellar carcinoma (搜索) its name. These altered stellate cells secrete signals that communicate with nearby T cells (搜索), causing them to migrate away from the cancer core toward the fibrous bands where they become trapped and ineffective.
AMD3100 Restores Immune Function
The researchers tested AMD3100, a drug currently FDA-approved for treating a different disorder, to block the signaling that sequesters T cells (搜索). Using patient tumor slices, the University of Washington team led by Dr. Venu Pillarisetty demonstrated that AMD3100 effectively mobilized T cells into the tumor core.
More significantly, combining AMD3100 with immune checkpoint inhibitors (搜索) further enhanced T-cell activation, leading to a significant increase in tumor cell death. This combination approach addresses both the sequestration problem and the activation of immune cells once they reach the tumor.
Clinical Translation Potential
The study's findings have immediate translational potential due to AMD3100's existing FDA approval status. "A compelling feature of this work is that AMD3100 is already FDA-approved, which can reduce risks and potentially speed up timelines for clinical trials in fibrolamellar carcinoma (搜索)," Sethupathy noted.
The research team is actively seeking liver cancer (搜索) clinicians interested in initiating clinical trials for this new treatment approach. The combination of an established safety profile and demonstrated efficacy in patient samples positions this strategy as a promising near-term therapeutic option.
Broader Implications for Cancer Immunotherapy
The research provides insights into why certain cancers resist immune checkpoint inhibitors (搜索). While these treatments are highly effective against liver, lung, kidney, and bladder cancers, as well as melanoma, many cancers including pancreatic, prostate, and brain tumors remain resistant. Understanding T-cell exclusion mechanisms could inform treatment strategies for other immunotherapy-resistant cancers.
The study was funded by the Fibrolamellar Cancer Foundation (搜索) and represents a collaborative effort between Cornell University and the University of Washington, with co-first authors including Andreas Stephanou, Jason Carter, and Lindsey Dickerson.